We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

61 hedge funds and large institutions have $35.1M invested in Cue Biopharma in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

168% more call options, than puts

Call options by funds: $201K | Put options by funds: $75K

22% more capital invested

Capital invested by funds: $28.7M → $35.1M (+$6.4M)

0.22% less ownership

Funds ownership: 1.21% → 0.99% (-0.22%)

5% less funds holding

Funds holding: 64 → 61 (-3)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

22% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 18

Holders
61
Holders Change
-3
Holders Change %
-4.69%
% of All Funds
0.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
14
Reduced
18
Closed
15
Calls
$201K
Puts
$75K
Net Calls
+$126K
Net Calls Change
+$81K

Top Buyers

Rank Fund Capital Flow
1
SPC
Slate Path Capital
New York
+$2.8M
2
BL
Bleichroeder LP
New York
+$934K
3
SCM
Silverarc Capital Management
Massachusetts
+$934K
4
PM
Prosight Management
Texas
+$899K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$212K

Top Sellers

Rank Fund Capital Flow
1
SMH
Sanders Morris Harris
Texas
-$2.41M
2
Renaissance Technologies
Renaissance Technologies
New York
-$867K
3
CC
Carlson Capital
Texas
-$518K
4
E
Ergoteles
New York
-$261K
5
AC
Apogem Capital
New York
-$247K
Name Holding Trade Value Shares
Change 		Change in
Stake
BHWM
51
Beaird Harris Wealth Management
Texas
$2.27K – – –
MCC
52
Money Concepts Capital
Florida
$2.04K +$2.19K +24 New
KFS
53
Kelly Financial Services
Massachusetts
$1.43K +$640 +7 +70%
Fidelity Investments
54
Fidelity Investments
Massachusetts
$1.38K +$1.46K +16 New
Dimensional Fund Advisors
55
Dimensional Fund Advisors
Texas
$1.3K +$10.7K +117 +0.8%
HI
56
Harbour Investments
Wisconsin
$1.25K – – –
AWM
57
Accel Wealth Management
Iowa
$906 – – –
ASN
58
Advisory Services Network
Georgia
$570 +$640 +7 New
BNP Paribas Financial Markets
59
BNP Paribas Financial Markets
France
$542 – – –
AAG
60
Armstrong Advisory Group
Massachusetts
$342 +$366 +4 New
E
61
Ergoteles
New York
– -$261K -3,902 Closed
AC
62
Apogem Capital
New York
– -$247K -3,687 Closed
Two Sigma Investments
63
Two Sigma Investments
New York
– -$76K -1,137 Closed
Susquehanna International Group
64
Susquehanna International Group
Pennsylvania
– -$87.1K -952 Closed
XT
65
XTX Topco
Cayman Islands
– -$61K -915 Closed
Marshall Wace
66
Marshall Wace
United Kingdom
– -$58K -874 Closed
RC
67
RBF Capital
California
– -$45K -667 Closed
Simplex Trading
68
Simplex Trading
Illinois
– -$50K -547 Closed
SSA
69
Schonfeld Strategic Advisors
New York
– -$34K -503 Closed
LP
70
LMR Partners
United Kingdom
– -$33K -488 Closed
EMG
71
ETF Managers Group
New Jersey
– -$23K -348 Closed
TRCT
72
Tower Research Capital (TRC)
New York
– -$6K -97 Closed
ACM
73
Aquatic Capital Management
Illinois
– -$1K -13 Closed
SPIA
74
Steward Partners Investment Advisory
New York
– -$1K -10 Closed
1 2
3

CUE Hedge Fund Activity: Q4 2022 in Review

61 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2022, worth a combined $35.1M — up 22% from $28.7M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of CUE and 12 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 14 added.

The largest buyer was Slate Path Capital, adding an estimated $2.8M. The largest seller was Sanders Morris Harris, cutting an estimated $2.41M.

  • 61 institutional investors held Cue Biopharma (CUE) as of Q4 2022, down from 64 in Q3 2022.
  • Funds reported $35.1M of Cue Biopharma stock for Q4 2022, up 22% quarter-over-quarter.
  • 12 funds opened new Cue Biopharma positions in Q4 2022 and 15 closed out, a net change of -3 holders.
  • The largest Cue Biopharma buyer in Q4 2022 was Slate Path Capital, an estimated $2.8M added.
  • The largest Cue Biopharma seller in Q4 2022 was Sanders Morris Harris, an estimated $2.41M sold.

Based on aggregated 13F filings for Q4 2022.